# A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

> **NCT01089023** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 95 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01089023
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2014-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01089023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01089023, "A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01089023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*